HC Wainwright restated their buy rating on shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) in a report issued on Monday, Stock Target Advisor reports. The firm currently has a $7.50 price target on the stock.
A number of other research firms have also issued reports on ELEV. SVB Leerink reiterated an outperform rating on shares of Elevation Oncology in a research note on Wednesday, July 27th. Wedbush lowered their target price on shares of Elevation Oncology from $15.00 to $8.00 and set an outperform rating on the stock in a research note on Friday, July 29th. Finally, JPMorgan Chase & Co. lowered shares of Elevation Oncology from an overweight rating to a neutral rating in a research note on Monday, August 8th.
Elevation Oncology Stock Down 1.8 %
Shares of ELEV opened at $1.12 on Monday. The company’s fifty day moving average is $1.26 and its 200-day moving average is $2.04. Elevation Oncology has a 12 month low of $1.02 and a 12 month high of $9.34. The firm has a market cap of $26.08 million, a price-to-earnings ratio of -0.44 and a beta of 0.82.
Institutional Trading of Elevation Oncology
Several hedge funds and other institutional investors have recently bought and sold shares of ELEV. Sio Capital Management LLC acquired a new stake in Elevation Oncology in the 4th quarter worth $1,505,000. Kennedy Capital Management Inc. acquired a new stake in Elevation Oncology in the 4th quarter worth $93,000. TCG Crossover Management LLC acquired a new stake in Elevation Oncology in the 4th quarter worth $3,341,000. Bailard Inc. acquired a new stake in Elevation Oncology in the 1st quarter worth $59,000. Finally, Marquette Asset Management LLC grew its position in Elevation Oncology by 332.5% in the 1st quarter. Marquette Asset Management LLC now owns 38,951 shares of the company’s stock worth $98,000 after purchasing an additional 29,945 shares during the last quarter. 74.04% of the stock is currently owned by institutional investors and hedge funds.
About Elevation Oncology
Elevation Oncology, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion.
- Get a free copy of the StockNews.com research report on Elevation Oncology (ELEV)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.